Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells

Hormone and Metabolic Research

Volumn 37, Issue 10, 2005, Pages 593-601

  Tenta, R ^a   Sourla, A ^a   Lembessis, P ^a   Luu The, V ^b   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Bone derived growth factors; PC 3 cell; PTHrP; Zoledronic acid

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BISPHOSPHONIC ACID DERIVATIVE; BONE DERIVED GROWTH FACTOR; DEXAMETHASONE; INTERLEUKIN 6; PARATHYROID HORMONE RELATED PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE CELL; BONE METASTASIS; CALCIUM TRANSPORT; CANCER CELL; CELL DIFFERENTIATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

BONE AND BONES; CELL LINE, TUMOR; DEXAMETHASONE; DIPHOSPHONATES; FIBROBLAST GROWTH FACTOR 2; FLUORESCENT ANTIBODY TECHNIQUE; GROWTH SUBSTANCES; HUMANS; IMIDAZOLES; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; RECEPTOR, PARATHYROID HORMONE, TYPE 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 27744449932     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870525     Document Type: Article

References (50)

1. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893-896
2. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10: 159-178
3. Ikeda K, Weir EC, Mangin M, Dannies PS, Kinder B, Deftos LJ, Brown EM, Broadus AE. Expression of messenger ribonucleic acids encoding a parathyroid hormone-like peptide in normal human and animal tissues with abnormal expression in human parathyroid adenomas. Mol Endocrinol 1988; 2: 1230-1236
4. Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol 1994; 126: 1611-1623
5. Qian J, Colbert MC, Witte D, Kuan CY, Gruenstein E, Osinska H, Lanske B, Kronenberg HM, Clemens TL. Midgestational lethality in mice lacking the parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology 2003; 144: 1053-1061
6. Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept 2002; 105: 109-120
7. Tovar Sepulveda VA, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology 2002; 143: 596-606
8. Koutsilieris M, Mitsiades C, Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 2000; 6: 251-267
9. Deftos LJ. Prostate carcinoma: production of bioactive factors. Cancer 2000; 88 (12 Suppl): 3002-3008
10. Sugihara A, Maeda O, Tsuji M, Tsujimura T, Nakata Y, Akedo H, Kotake T, Terada N. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Oncol Rep 1998; 5: 1389-1394
11. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002; 95: 1028-1036
12. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152: 1-9
13. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 333-349
14. Zayzafoon M, Abdulkadir SA, McDonald JM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004; 279: 3662-3670
15. Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 1998; 52: 341-347
16. Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 1999; 38: 313-316
17. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001; 86: 5729-5736
18. Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin Investig Drugs 2002; 11: 283-293
19. Hsieh CL, Kubo H, Chung LW. Gene therapy for prostate cancer bone metastasis. Gene therapy targeting bone metastasis. Cancer Treat Res 2004; 118: 231-290
20. Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 2004; 63: 120-125
21. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339: 398-400
22. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002; 62: 5564-5570
23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
24. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882
25. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45: 26-34
26. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004; 45: 521-528; discussion 528-529
27. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-2608
28. Papapoulos SE, Hamdy NA, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 2000; 88 (Suppl): 3047-3053
29. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23
30. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55: 2122-2128
31. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest 1993; 11: 25-32
32. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994; 43: 675-679
33. Dougherty KM, Blomme EA, Koh AJ, Henderson JE, Pienta KJ, Rosol TJ, McCauley LK. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999; 59: 6015-6022
34. Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 2004; 59: 120-131
35. Wu G, Iwamura M, di Sant'Agnese PA, Deftos LJ, Cockett AT, Gershagen S. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue. Urology 1998; 51 (Suppl): 110-120
36. Wojcik SF, Capen CC, Rosol TJ. Expression of PTHrP and the PTH/PTHrP receptor in purified alveolar epithelial cells, myoepithelial cells, and stromal fibroblasts derived from the lactating rat mammary gland. Exp Cell Res 1999; 248: 415-422
37. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-723
38. Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001; 10: 1099-1115
39. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593
40. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 1997; 17: 1541-1549
41. Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003; 10: 279-289
42. Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexi D, Koutsilieris M. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Mol Med 2002; 8: 667-675
43. Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res 1997; 17: 1461-1465
44. Pizzi H, Gladu J, Carpio L, Miao D, Goltzman D, Rabbani SA. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology 2003; 144: 858-867
45. Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999; 39: 187-197
46. Hullinger TG, McCauley LK, DeJoode ML, Somerman MJ. Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate 1998; 36: 14-22
47. Lam MH, Thomas RJ, Martin TJ, Gillespie MT, Jans DA. Nuclear and nucleolar localization of parathyroid hormone-related protein. Immunol Cell Biol 2000; 78: 395-402
48. Jans DA, Thomas RJ, Gillespie MT. Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles. Vitam Horm 2003; 66: 345-384
49. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 1997; 80 (Suppl): 1572-1580
50. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 1995; 26: 260-269